About us
Learn more about Masinova, our mission, and how we're bringing rigor and reproducibility to drug development. Discover our values and commitment to developing safer, more effective therapies.
Our mission
At Masinova, our mission is to turn rigorous, reproducible science into safe, effective therapies that can move efficiently from discovery through preclinical development and into Phase I clinical testing. We are dedicated to advancing therapeutic R&D with Quality-by-Design principles, ensuring reproducibility, safety, and efficient translation.
Our values
Our approach to drug development is defined by three core values:
Rigor & Reproducibility: We prioritize disciplined experimental design, high-quality data generation, and repeatable results to build strong evidence packages.
Safety-by-Design: We integrate safety and risk assessment early—so programs are developed with a clear path to IND-enabling work and first-in-human readiness.
Efficient Translation: We focus on decision-focused milestones and development readiness to move programs efficiently from discovery through preclinical development and into Phase I.
Founder CEO
Masinova is founded and led by Mandana Daraei Fathabad, Founder & CEO, bringing a rigor-led, QbD-driven approach to therapeutic R&D. I translate precise research into development-ready therapy programs—structured for reproducibility, early safety integration, and efficient progress from preclinical milestones toward Phase I..
"Masinova is committed to raising the standard for reproducible, Quality-by-Design drug development."
The Masinova Team